恩替卡韦联合细胞因子诱导的杀伤细胞序贯治疗慢性乙型肝炎患者树突状细胞相关功能观察  

Functional status of DC in patients with chronic hepatitis B treated with CIK combined with entecavir

作　　者：王少扬[1,2] 刘海周[1,2] 马卫闽[1,2] 王贤[1,2] 谢丽平[1,2] 谢志红[1,2] 

机构地区：[1]南京军区福州总医院感染科 [2]福建医科大学福总临床医学院传染病学教研室,福州350003

出　　处：《现代免疫学》2015年第4期285-288,共4页Current Immunology

基　　金：福建省自然科学基金项目(2011J01236)

摘　　要：观察恩替卡韦联合细胞因子诱导的杀伤细胞(cytokine-induced kill cells,CIK)序贯治疗慢性乙型肝炎患者DC功能变化,为指导CIK联合核苷(类)药物抗病毒治疗提供理论依据。以15例接受恩替卡韦联合CIK序贯治疗的慢性乙型肝炎患者为观察对象,单独接受CIK治疗患者为对照,分别在治疗前、HBVDNA<500IU/ml及CIK治疗2周后流式细胞技术测定DC表面共刺激分子CD1a、CD80、CD83及HLA-DR表达水平,同时淋巴细胞增殖实验评估DC细胞功能。结果显示15例恩替卡韦联合CIK序贯治疗患者同治疗前相比在接受恩替卡韦治疗并达到HBVDNA<500IU/ml时仅有HLA-DR表达水平高于治疗前,其它共刺激分子标志物及淋巴细胞增殖能力没有显著变化。CIK序贯治疗后DC共刺激分子标志物和HLA-DR水平明显升高,并且淋巴细胞增殖能力也明显升高。单独CIK治疗患者同治疗前比较DC表面分子标志物水平及淋巴细胞增殖能力均无变化,同联合治疗组相比DC标志物水平和淋巴细胞增殖能力均低于联合治疗组。以上结果提示恩替卡韦联合CIK序贯治疗明显提高慢性乙型肝炎患者DC共刺激分子及HLA-DR表达,并诱导免疫细胞应答功能,恩替卡韦联合CIK序贯治疗可能通过增强DC相关功能提高慢性乙肝患者的抗病毒疗效。To observe the function of dendritic cells （DC） in chronic hepatitis B（CHB） patients during the treatment by cyto- kine-indueed kill cells （CIK） combined with entecavir, 15 CHB patients who received CIK combined with entecavir were en- rolled in this study. The DC was induced from peripheral blood mononuclear cells （PBMC） and surface markers were examined by flow cytometry at different time points during the treatment. The function of DC was evaluated by mixed lymphocyte reac- tion. Ten CHB patients who only received CIK were enrolled as control. The results showed, Expression of DC phenotypes CDla / CD83/CDS0 in the CHB patients whose HBVDNA reached undetectable level following treatment with entecarvia were remained unchanged except for level of HLA-DR that was increased significantly, and mixed lymphocyte reaction was also not changed, however, after CIK treatment, all of DC phenotypes expression and allo-stimulatory capacity of DC were increased significantly ;moreover, compared with the control group, expression of DC phenotypes and allo-stimulatory capacity of DC were increased significantly. Our results suggest that CIK combined with entecavir results in an improvement in the functional- ity of DC and may be improved therapy for CHB patients through modulation of function of DC.

关 键 词：乙型肝炎 细胞因子诱导的杀伤细胞 树突状细胞 恩替卡韦 

分 类 号：R392.12[医药卫生—免疫学]